Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment

被引:0
|
作者
Li, Shaobo [1 ,2 ]
Zhang, Min [3 ]
Liu, Jin [4 ]
Liu, Shaojun [3 ]
Zhu, Chen [1 ]
Shang, Da [3 ]
Guan, Yi [3 ]
Wang, Qian [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China
[2] Inner Mongolia Med Univ, Peking Univ Canc Hosp, Dept Nucl Med, Affiliated Canc Hosp, Inner Mongolia Campus, Hohhot 010020, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200040, Peoples R China
[4] Naval Med Univ, Changzheng Hosp, Dept Hematol Myeloma & Lymphoma Ctr, Shanghai 200003, Peoples R China
关键词
Multiple myeloma; Myeloma nephropathy; Renal impairment recovery; Risk nomogram; BORTEZOMIB-BASED CHEMOTHERAPY; CAST NEPHROPATHY; STAGING SYSTEM; HIGH-CUTOFF; FAILURE; HEMODIALYSIS; DISEASE; SAFETY; INDEPENDENCE; MULTICENTER;
D O I
10.1016/j.currproblcancer.2023.100962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine risk factors affecting renal recovery in newly diagnosed multiple myeloma (NDMM) patients with renal impairment (RI) and establish a risk nomogram. This multi-center, retrospective cohort study included 187 NDMM patients with RI, 127 of whom were admitted to Huashan Hospital and assigned to the training cohort and 60 were admitted to Changzheng Hospital and assigned to the external validation cohort. The baseline data of the 2 cohorts were compared, and survival and renal recovery rates were analyzed. Independent risk factors affecting renal recovery were determined by binary logistic regression analysis, and a risk nomogram was established and subsequently tested in the external validation cohort. Results: The median overall survival (OS) improved in patients who achieved renal recovery etc within 6 courses of MM directed treatment compared with patients without renal recovery. Median time to renal recovery was 2.65 courses, and the cumulative renal recovery rate during the first 3 courses was 75.05%. Involved serum free light chain (sFLC) ratio of > 120 at diagnosis, time from renal impairment to treatment > 60 days, and a hematologic response without a very good partial remission (VGPR) or better resulted as independent risk factors for renal recovery during the first 3 courses. The established risk nomogram had good discriminative ability and accuracy. Involved sFLC was a key factor affecting renal recovery. Starting treatment as soon as possible after detecting RI and achieving deep hematologic remission during the first 3 courses of treatment helped achieve renal recovery and improve prognosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Management of multiple myeloma-related renal impairment: recommendations from the International MyelomaWorking Group
    Dimopoulos, Meletios A.
    Merlini, Giampaolo
    Bridoux, Frank
    Leung, Nelson
    Mikhael, Joseph
    Harrison, Simon J.
    Kastritis, Efstathios
    Garderet, Laurent
    Gozzetti, Alessandro
    van de Donk, Niels W. C. J.
    Weisel, Katja C.
    Badros, Ashraf Z.
    Beksac, Meral
    Hillengass, Jens
    Mohty, Mohamad
    Ho, P. Joy
    Ntanasis-Stathopoulos, Ioannis
    Mateos, Maria-Victoria
    Richardson, Paul
    Blade, Joan
    Moreau, Philippe
    San-Miguel, Jesus
    Munshi, Nikhil
    Rajkumar, S. Vincent
    Durie, Brian G. M.
    Ludwig, Heinz
    Terpos, Evangelos
    LANCET ONCOLOGY, 2023, 24 (07) : E293 - E311
  • [12] Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report
    Wu, Tao
    Zhou, Jinmao
    Wang, Cunbang
    Wang, Binbin
    Zhang, Shuting
    Bai, Hai
    ONCOLOGY LETTERS, 2017, 14 (06) : 7318 - 7322
  • [13] Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Goldschmidt, Hartmut
    Alegre, Adrian
    Mark, Tomer
    Niesvizky, Ruben
    CANCER TREATMENT REVIEWS, 2012, 38 (08) : 1012 - 1019
  • [14] Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
    Yang, Guangzhong
    Chen, Wenming
    Wu, Yin
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (02) : 155 - 160
  • [15] Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study
    Wei, Wei
    Shi, Haotian
    Chen, Haimin
    Chen, Xiaoling
    Peng, Rong
    Yu, Wenjun
    Wu, Lixia
    Zhou, Nian
    Zhao, Wenhao
    Xu, Weiwei
    Zhou, Yan
    Yu, Jingjing
    Wei, Daolin
    Zhou, Fan
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
  • [16] Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry
    Courant, Maxime
    Orazio, Sebastien
    Monnereau, Alain
    Preterre, Julie
    Combe, Christian
    Rigothier, Claire
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (03) : 482 - 490
  • [17] Monoclonal Immunoglobulin-Associated Renal Lesions in Patients with Newly Diagnosed Multiple Myeloma: A Report from a Single Center
    Lin, Zi-Shan
    Yu, Xiao-Juan
    Zhang, Xu
    Wang, Su-Xia
    Cen, Xi-Nan
    Zhou, Fu-De
    Zhao, Ming-Hui
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 3879 - 3888
  • [18] Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients
    Yan, Ge
    Li, Huangmin
    Zhang, Yiding
    Xia, Chenyan
    Wang, Mengxiao
    Jia, Yu
    Shang, Jin
    Zhao, Zhanzheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [19] Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
    Roussou, Maria
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Grapsa, Irini
    Psimenou, Erasmia
    Gika, Dimitra
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    LEUKEMIA RESEARCH, 2010, 34 (10) : 1395 - 1397
  • [20] Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
    Gonsalves, W. I.
    Leung, N.
    Rajkumar, S. V.
    Dispenzieri, A.
    Lacy, M. Q.
    Hayman, S. R.
    Buadi, F. K.
    Dingli, D.
    Kapoor, P.
    Go, R. S.
    Lin, Y.
    Russell, S. J.
    Lust, J. A.
    Zeldenrust, S.
    Kyle, R. A.
    Gertz, M. A.
    Kumar, S. K.
    BLOOD CANCER JOURNAL, 2015, 5 : e296 - e296